12 Best Biotech Penny Stocks To Invest In Now

Page 2 of 11

10. Autolus Therapeutics plc (NASDAQ:AUTL)

Number of Hedge Fund Investors: 20

Stock Price as of December 26: $2.25

Autolus Therapeutics plc (NASDAQ:AUTL) is a biopharmaceutical company dedicated to the development and commercialization of next-generation, programmed T-cell therapies for the treatment of cancer and autoimmune diseases. The company’s lead product, AUCATZYL, recently received FDA approval for the treatment of relapsed or refractory adult ALL (Acute Lymphoblastic Leukemia).

With the recent approval of AUCATZYL, Autolus Therapeutics plc (NASDAQ:AUTL) is now fully focusing on a successful commercial launch. The company has been diligently preparing for this by ensuring that all necessary elements are in place to deliver this groundbreaking therapy to patients. A key aspect of this preparation has been the onboarding of treatment centers. Currently, over 30 centers across the United States are ready to activate, which covers approximately 60% of the target patient population. By the end of 2025, Autolus Therapeutics plc (NASDAQ:AUTL) aims to expand this network to 90% coverage to ensure access to the therapy. The company has also invested in a state-of-the-art commercial manufacturing facility, The Nucles, which has the capacity to produce up to 2,000 doses annually to support the needs of patients in both the US and Europe.

Autolus Therapeutics plc (NASDAQ:AUTL) is also expanding the utility of its lead candidate, obe-cel. The company is conducting clinical trials to explore the potential of obe-cel in treating other conditions, including systemic lupus and multiple myeloma. Furthermore, Autolus Therapeutics plc (NASDAQ:AUTL) has been building a strong, experienced team with a track record in both commercial and clinical development. The company has also been focused on enhancing scientific communication, presenting data at key medical conferences, and preparing for peer-reviewed publications.

Page 2 of 11